



PEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY

Conde, R.¹; Soares, C.¹; Barbeita, P.¹; Cunha, T.¹; Rocha, P.¹
¹ Unidade Local de Saúde de Santo António, Porto, Portugal

INTRODUCTION

- ✓ **Checkpoint inhibitors (ICI)** are used in several cancers but pose drug management challenges, specially adverse events (AE).
- ✓ **Clinical benefits** introduce a new rechallenge paradigm despite the **risk of serious AE**.
- ✓ The presented **case** is unique as it underscores the severe repercussions of **immune-mediated toxicity of Pembrolizumab**.



Physical parameters

Male
Age of 70's
Caucasian
Height 1,64m
Weight 58kg



Patient medical history


Type 2 diabetes
Hypertension
Nephrolithiasis
Benign prostatic hyperplasia
Pacemaker implant due to bradycardia



Medication

Metformin
Amlodipine
Perindopril/indapamide
Acetylsalicylic acid
Dutasteride
Afluzosin
Lactulose
Sodium picosulfate

CHRONOLOGICAL EVOLUTION




CONCLUSION

- ✓ **Acute AE**: reasonable well treated by **managing symptoms, ICI treatment** and using high-doses of **corticoids/immunosuppressants** [1,2].



In this report it wasn't enough (**off-label therapies**)

- ✓ **Avoid late detection** of the relation between the **AE** and the therapeutics -> irreversible G3 and G4 myopathy.
- ✓ Highlight of the importance of managing immune-mediated AE: **patient empowerment** and **health literacy**.
- ✓ Importance of creating **hospital circuits** able to **detect on time the AE** in patient under ICI -> **Red Flags** ▶



[1] Johnson, Douglas B., et al: Immune-checkpoint inhibitors: long-term implications of toxicity, Nature Reviews Clinical Oncology 19, Nr. 4 2022, 254–267.

[2] www.uptodate.com/contents/toxicities-associated-with-immune-checkpoint-inhibitors (accessed 07/08/2023)